Opinion|Videos|November 26, 2025
Challenges with Current Psoriasis Therapies
Experts discuss the future of psoriasis treatment, highlighting the potential of oral therapies to enhance patient adherence and quality of life.
Advertisement
Episodes in this series
Panelists discuss the questions below in this video.
What are the biggest challenges you face with current psoriasis therapies in terms of durability, access, and adherence? What limitations do providers and patients face with therapies such as biologics or oral small molecules, and what quality of life concerns remain inadequately addressed by current therapies?
Advertisement
Related to this article
Robert Mentz, MD, discusses mentorship, trial recruitment, journal growth, and surgical partnerships in heart failure care.
Juanita Mora, MD, of Chicago Allergy Center discusses strategies from boosters and antiviral prophylaxis to specialist counseling.
Stay updated with the latest healthcare breakthroughs, including 96-week durability data for GSK’s bepirovirsen in hepatitis B, and more.
The FDA approved asundexian with antiplatelet therapy after non-cardioembolic ischemic stroke or high-risk TIA, based on OCEANIC-STROKE data.
Clinicians at ACAAI 2026 will see late-breaking HAE, anaphylaxis, urticaria, and food allergy data, plus exclusive expert interviews.
Mona Shahriari, MD, and Valerie D. Callender, MD, discuss trial diversity, better outcome measures, and how investigators can earn patient trust.
Compass Pathways completed its NDA for COMP360 based on 2 phase 3 trials and a phase 2b study in > 1000 participants with highly chronic TRD.
In a UCB-funded network meta-analysis of 17 trials, bimekizumab ranked first on HiSCR50, HiSCR75, and IHS4-55 among HS drugs at Weeks 12 - 16.
Advertisement
Advertisement
Trending on HCPLive
1
Single Dose of CIDEB siRNA Normalizes Liver Fat in MASLD Through 36 Weeks
2
COMP360 Psilocybin NDA Submitted to FDA for Treatment-Resistant Depression
3
Asundexian Receives FDA Approval for Secondary Stroke Prevention
4
What’s New in the 2027 GOLD Report for COPD
5